Year Founded
1903
Ownership
Private
Employees
~5000
Stage
Commercial
Modalities
Small molecule

Xellia Pharmaceuticals General Information

Leading global supplier of anti-infective treatments, particularly vancomycin and colistimethate sodium (CMS). Supplies APIs to over 500 pharmaceutical companies across 80 countries.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Copenhagen,
Denmark

Drug Pipeline

vancomycin
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Xellia Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Xellia Pharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Xellia Pharmaceuticals's complete valuation and funding history, request access »

Xellia Pharmaceuticals Investors

Novo Holdings A/S (sole owner since acquisition in2013)
Investor Type: Venture Capital
Holding: Minority